|
|
Article: Schering-Plough Announces FDA Approval of CLARINEX(R) (Desloratadine) for Treatment of Seasonal Allergic Rhinitis; New, Once-Daily, Nonsedating Therapy Provides 24-Hour Relief Of Nasal and Non-Nasal Symptoms of Seasonal Allergies.
- Article from:
- PR Newswire
- Article date:
- December 21, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
KENILWORTH, N.J. -- Schering-Plough Corporation announced today that CLARINEX(R) (desloratadine) 5 mg Tablets has received marketing clearance from the U.S. Food and Drug Administration (FDA) for the treatment of seasonal allergic rhinitis (SAR) in adults and children 12 years of age and older. The company expects CLARINEX launch activities to begin in January 2002.
CLARINEX is a new, once-daily, nonsedating antihistamine that provides 24-hour relief from the symptoms of SAR. An H-1 receptor antagonist, CLARINEX Tablets taken once daily in clinical trials significantly reduced total symptom scores of the nasal and non-nasal symptoms of seasonal allergies.
...